LexDanaLexDanabeta
New SessionSearchOfficial RankingsInsightsPricing
© LexDana · beta
LexDanaLexDanabeta
New SessionSearchOfficial RankingsInsightsPricing
LexDanaLexDanabeta

Insights

Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.

AllCopyright & Trade Secrets14Federal Circuit179Pharma & ANDA40PTAB150Supreme Court9USPTO Policy27Patent Litigation55Patent Prosecution20ITC / Section 33732Trademark43Unsorted35

Tagged federal circuit opinions · clear

Federal Circuit

Description Prescription

Written by : Brandon D. Hupka & Hans L. Mayer REGENTS OF THE UNIVERSITY OF MINNESOTA V. GILEAD SCIENCES, INC. Before Lourie , Dyk, and Stoll. Appeal from the Patent Trial and Appeal Board. Summary : For drug patents, adequate written description of a broad…

March 6, 2023·Federal Circuit·2 min read
Federal Circuit

Fresh From the Bench: Latest Federal Circuit Court Case

CASE OF THE WEEK Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC , Appeal No. 2023-1186 (Fed. Cir. Feb. 24, 2023) In this week’s Case of the Week, the Federal Circuit affirmed a permanent injunction requiring appellant Jazz…

February 27, 2023·Federal Circuit·2 min read
Federal Circuit

Patent Directed to System for Controlling Access to Drugs Is Not Listable in the Orange Book

Written by : Tyler S. Cox & Kendall Loebbaka JAZZ PHARMACEUTICALS, INC. v. AVADEL CNS PHARMACEUTICALS, LLC Before Lourie, Reyna, and Taranto. Appeal from the United States District Court for the District of Delaware. Summary: A patent directed to a system…

February 27, 2023·Federal Circuit·2 min read
← NewerPage 23 of 23
LexDana
AskSearchRankingsInsightsPricingProfileContactTermsPrivacy
The LexDana Docket
Monthly — what shipped, who moved, what we published.
© 2026 LexDana, Inc.·Powered by Patexia data